公开(公告)号：US09156886B2

公开(公告)日：2015-10-13

申请号：US13734074

申请日：2013-01-04

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Guoqiang Wang ,  Jiang Long ,  Xuri Gao

IPC: A61K38/13 ,  A01N37/18 ,  A61K38/00 ,  A61P31/12 ,  A61K31/18 ,  C07K7/52 ,  A61K31/7088 ,  A61K38/21 ,  A61K45/00

CPC classification number: A61K38/13 ,  A61K31/7088 ,  A61K38/21 ,  A61K45/00 ,  A61K45/06 ,  C07K7/52 ,  C07K7/645 ,  Y02A50/463

Abstract: The present invention relates to cyclosporin analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporin analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.

Abstract translation: 本发明涉及对HCV具有抗病毒活性的环孢菌素类似物，可用于治疗HCV感染。 更具体地，本发明涉及新的环孢菌素类似物化合物，含有这些化合物的组合物及其使用方法，以及制备这些化合物的方法。

公开(公告)号：US12011425B2

公开(公告)日：2024-06-18

申请号：US18101258

申请日：2023-01-25

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yao-Ling Qiu ,  Xuri Gao ,  Jorden Kass ,  Hui Cao ,  Wei Li ,  Xiaowen Peng ,  Byung-Chul Suh ,  Yat Sun Or

IPC: A61K31/167 ,  A61K31/337 ,  A61K31/34 ,  A61K31/351 ,  A61K31/357 ,  A61K31/397 ,  A61K31/401 ,  A61K31/4015 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4192 ,  A61K31/421 ,  A61K31/426 ,  A61K31/4409 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/513 ,  A61K31/7028 ,  A61P31/20 ,  C07C303/00 ,  C07C317/44 ,  A61K45/06

CPC classification number: A61K31/167 ,  A61K31/337 ,  A61K31/34 ,  A61K31/351 ,  A61K31/357 ,  A61K31/397 ,  A61K31/401 ,  A61K31/4015 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4192 ,  A61K31/421 ,  A61K31/426 ,  A61K31/4409 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/513 ,  A61K31/7028 ,  A61P31/20 ,  C07C303/00 ,  C07C317/44 ,  A61K45/06 ,  C07B2200/05 ,  C07C2601/02 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/10 ,  C07C2601/14 ,  C07C2601/16 ,  C07C2602/44 ,  C07C2602/50

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:

X-A-Y-L-R  (I)

which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20230151019A1

公开(公告)日：2023-05-18

申请号：US17983501

申请日：2022-11-09

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Hui Cao ,  Wei Li ,  Xuri Gao ,  Jiajun Zhang ,  Xiaowen Peng ,  Jorden Kass ,  Ruichao Shen ,  Guoqiang Wang ,  Yat Sun Or

IPC: C07D487/10 ,  A61P31/14

CPC classification number: C07D487/10 ,  A61P31/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:




which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11472808B2

公开(公告)日：2022-10-18

申请号：US16892464

申请日：2020-06-04

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yao-Ling Qiu ,  Xiaowen Peng ,  Wei Li ,  Xuri Gao ,  Jorden Kass ,  Byung-Chul Suh ,  Hui Cao ,  Jiajun Zhang ,  Yat Sun Or

IPC: A61K31/519 ,  C07D487/04 ,  C07D519/00 ,  A61K45/06

Abstract: The present invention discloses substituted pyrrolo[1,2-c]pyrimidines, such as the compound which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US11352363B1

公开(公告)日：2022-06-07

申请号：US17479530

申请日：2021-09-20

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Xuri Gao ,  Ruichao Shen ,  Yong He ,  Jiajun Zhang ,  Joseph D. Panarese ,  Hui Cao ,  Xuechao Xing ,  Yat Sun Or

IPC: C07D487/10 ,  A61P31/14

Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable slat thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20220162217A1

公开(公告)日：2022-05-26

申请号：US17479530

申请日：2021-09-20

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Xuri Gao ,  Ruichao Shen ,  Yong He ,  Jiajun Zhang ,  Joseph D. Panarese ,  Hui Cao ,  Xuechao Xing ,  Yat Sun Or

IPC: C07D487/10 ,  A61P31/14

Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable slat thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20210283077A1

公开(公告)日：2021-09-16

申请号：US17166046

申请日：2021-02-03

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yao-Ling Qiu ,  Xuri Gao ,  Jorden Kass ,  Hui Cao ,  Wei Li ,  Xiaowen Peng ,  Byung-Chul Suh ,  Yat Sun Or

IPC: A61K31/167 ,  A61K31/4164 ,  A61K31/34 ,  A61K31/357 ,  A61K31/4409 ,  A61K31/426 ,  A61K31/4015 ,  A61K31/4439 ,  A61K31/415 ,  A61K31/421 ,  A61K31/4192 ,  A61K31/351 ,  A61K31/397 ,  A61K31/337 ,  A61K31/47 ,  A61K31/513 ,  A61K31/7028 ,  A61P31/20 ,  A61K31/401 ,  C07C303/00 ,  C07C317/44

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US10934306B2

公开(公告)日：2021-03-02

申请号：US16715602

申请日：2019-12-16

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yao-Ling Qiu ,  Xuri Gao ,  Wei Li ,  Hui Cao ,  Meizhong Jin ,  Jorden Kass ,  Xiaowen Peng ,  Yat Sun Or

IPC: C07D493/08 ,  C07C317/44 ,  C07C323/62 ,  A61K31/167 ,  A61K31/18 ,  A61K31/196 ,  A61K31/215 ,  A61K31/223 ,  A61K31/277 ,  A61K31/325 ,  A61K31/335 ,  A61K31/336 ,  A61K31/341 ,  A61K31/351 ,  A61K31/357 ,  A61K31/365 ,  A61K31/39 ,  A61K31/401 ,  A61K31/41 ,  A61K31/415 ,  A61K31/416 ,  A61K31/4164 ,  A61K31/421 ,  A61K31/426 ,  A61K31/439 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4409 ,  A61K31/4425 ,  A61K31/445 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/655 ,  C07B59/00 ,  C07C235/56 ,  C07C311/53 ,  C07C317/32 ,  C07C323/42 ,  C07D207/16 ,  C07D211/54 ,  C07D213/52 ,  C07D213/81 ,  C07D213/89 ,  C07D231/12 ,  C07D233/64 ,  C07D257/04 ,  C07D261/02 ,  C07D261/08 ,  C07D261/20 ,  C07D263/52 ,  C07D277/26 ,  C07D295/088 ,  C07D303/26 ,  C07D303/34 ,  C07D307/32 ,  C07D307/33 ,  C07D309/08 ,  C07D313/04 ,  C07D317/72 ,  C07D327/10 ,  C07D401/04 ,  C07D451/04 ,  C07D493/04

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20200377519A1

公开(公告)日：2020-12-03

申请号：US16891401

申请日：2020-06-03

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yao-Ling Qiu ,  Xuri Gao ,  Xiaowen Peng ,  Wei Li ,  Jorden Kass ,  Hui Cao ,  Byung-Chul Suh ,  Jiajun Zhang ,  Yat Sun Or

IPC: C07D498/20 ,  C07D487/20

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US10723733B2

公开(公告)日：2020-07-28

申请号：US16210492

申请日：2018-12-05

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yao-Ling Qiu ,  Xiaowen Peng ,  Jorden Kass ,  Xuri Gao ,  Wei Li ,  Hui Cao ,  Byung-Chul Suh ,  Yat Sun Or

IPC: C07D487/04 ,  C07D471/04 ,  C07D417/14 ,  C07D413/14 ,  A61P31/14

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.